Sofinnova Partners

Antoine Papiernik sat down with Shani Alexander to discuss what’s ahead for MedTech in 2025. He notes, “I see more financing being available for med-tech companies this year compared to last.” The article explores how European companies seeking capital may find a more favorable fundraising environment this year. Read the full piece to learn more—link in the comments.  

Congratulations to Latent Labs, a Sofinnova Partners portfolio company, on emerging from stealth with a $50M funding. Founded by Simon Kohl, previously a co-lead of DeepMind’s protein design team and a senior research scientist on DeepMind’s AlphaFold2, the Nobel Prize winning project led by Demis Hassabis and John Jumper.   Latent Labs is developing AI foundation models to make biology programable. Sofinnova Partners and Radical Ventures are honored to have co-led the round to accelerate Latent's groundbreaking work in reprogramming biology.

As we share more on how our team uses Sofinnova AI, we explored which European centers drive breakthroughs for high unmet medical need diseases. See which hubs Sofinnova AI identifies.

Team Sofinnova Partners was all over the AI Action Summit in Paris this week. AI isn’t just reshaping life sciences, it’s the future. Our own AI platform, Sofinnova.AI, is already revolutionizing how we invest and find the breakthroughs of tomorrow, leveraging our 50+ years of proprietary data. Our Digital Medicine strategy is working with exceptional founders at the intersection of biology, computation and data. The future of AI in France has never looked brighter.

BioWorld Medtech’s Shani Alexander explores European VCs' sentiment on medtech exit opportunities this year. The overall outlook is positive, with our own Antoine Papiernik, Managing Partner at Sofinnova Partners, emphasizing that “Europe has a lot to sell given that a lot of amazing technologies are created here.” Sofinnova Partners saw two portfolio companies bought out in the recent acquisition wave: LimFlow, which was created in its accelerator program and Shockwave Medical, in which it was the first institutional shareholder.  The article also highlighted Moon Surgical as an example of the kind of European companies that are at the right stage of development with life transforming technologies. Checkout the link in the comments to read the full piece.

2025 is set to be a year of change in clinical trials, according to pharmaphorum. Our Partners Maina Bhaman and Simon Turner, share their take on key trends for the year ahead. - Companies working on GLP-1 therapies are refining technology and exploring new mechanisms and combination therapies to compete with established drugs. - AI’s potential to reduce risk and cost at all levels of the clinical trial process will benefit all stakeholders. Link to full text in the comments.

The Keys To Biotech Success: People And Relationships https://lnkd.in/eKgey2cA - By Henrijette Richter, Managing Partner, Sofinnova Partners Learn the key factors that drive biotech start-up success, including the importance of strong networks, experienced leadership, strategic partnerships, and a focus on unmet patient needs.

At Sofinnova Partners, we partner with companies advancing cancer prevention, detection, and treatment. “United by Unique” is the World Cancer Day theme, which places people at the center of care and their stories at the heart of the conversation. This World Cancer Day, we stand united with innovators, researchers, patients, and their families, to raise awareness and drive progress in the fight against cancer. #unitedbyunique

🌟 Cure51 is pioneering cancer treatment research by studying extraordinary survivors. With a network of over 150 hospitals and insights from 1,500 "miraculous patients," the company is uncovering biological pathways for breakthrough therapies. In March 2024, the company raised €15 million in a round led by venture capital firm Sofinnova Partners. Read more: https://lnkd.in/epj8EgvP #UnitedByUnique #WorldCancerDay #PrivateEquity #VentureCapital #Infrastructure

Today, on World Cancer Day Labiotech.eu explores the key trends in cancer therapeutics to watch for in 2025. Maina Bhaman, Partner at Sofinnova Partners, shares her views: “Personalized medicine is revolutionizing cancer treatment, making therapies more precise and less invasive. Advances in early detection and targeted treatments offer real progress, though cancer’s complexity means continued innovation is key.” Read the full piece to find out what innovations are underway to improve cancer care in 2025.